|
JP2004517805A
(ja)
|
2000-06-30 |
2004-06-17 |
ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー |
ケモカイン受容体活性調節剤としてのｎ−ウレイドヘテロシクロアルキル−ピペリジン
|
|
EP1318811B1
(en)
|
2000-08-17 |
2006-08-30 |
Merck & Co., Inc. |
Cyclopentyl modulators of chemokine receptor activity
|
|
ATE319703T1
(de)
|
2001-07-02 |
2006-03-15 |
|
Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
|
|
JO2479B1
(en)
|
2002-04-29 |
2009-01-20 |
ميرك شارب اند دوم ليمتد |
Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
|
|
US20060030582A1
(en)
|
2002-04-29 |
2006-02-09 |
Demartino Julie |
Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
|
|
EP1501507B1
(en)
|
2002-04-29 |
2008-05-28 |
Merck & Co., Inc. |
Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
|
|
DE60322877D1
(de)
|
2002-04-29 |
2008-09-25 |
Merck Sharp & Dohme |
Tetrahydropyranylcyclopentyltetrahydroisochino-linmodulatoren der chemokinrezeptoraktivität
|
|
EP1558599A4
(en)
|
2002-10-30 |
2007-06-27 |
Merck & Co Inc |
HETEROARYLPIPERIDINE MODULATORS DERCHEMOKIN RECEPTORACTIVITY
|
|
WO2004076411A2
(en)
|
2003-02-24 |
2004-09-10 |
Merck & Co., Inc. |
Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity
|
|
AU2004222336B2
(en)
|
2003-03-18 |
2010-06-03 |
Merck Sharp & Dohme Corp. |
Amino cyclobutylamide modulators of chemokine receptor activity
|
|
AU2004231087B2
(en)
|
2003-04-15 |
2007-01-04 |
Merck Sharp & Dohme Corp. |
Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
|
|
AU2004232939A1
(en)
|
2003-04-17 |
2004-11-04 |
Merck Sharp & Dohme Corp. |
Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
|
|
WO2004110376A2
(en)
|
2003-06-06 |
2004-12-23 |
Merck & Co., Inc. |
Ccr-2 antagonists for treatment of neuropathic pain
|
|
MXPA06004647A
(es)
|
2003-10-27 |
2006-06-27 |
Merck & Co Inc |
Sal antagonista de ccr-2.
|
|
AR045875A1
(es)
|
2003-10-27 |
2005-11-16 |
Merck & Co Inc |
Procedimiento para la preparacion del antagonista ccr-2
|
|
US20070117797A1
(en)
|
2004-01-02 |
2007-05-24 |
Goble Stephen D |
Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
|
|
JP2007522219A
(ja)
|
2004-02-12 |
2007-08-09 |
メルク エンド カムパニー インコーポレーテッド |
ケモカイン受容体活性のアミノ複素環式調節物質
|
|
BRPI0510665A
(pt)
|
2004-05-11 |
2007-12-04 |
Incyte Corp |
3-(4-heteroarilcicloexilamino) ciclopentano-carboxiamidas como moduladores de receptores de quimiocinas
|
|
PA8653301A1
(es)
|
2004-11-22 |
2006-11-09 |
Incyte Corp Incyte Corp |
Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
|
|
WO2006074265A2
(en)
|
2005-01-06 |
2006-07-13 |
Merck & Co., Inc. |
Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
|
|
US8519135B2
(en)
|
2006-07-14 |
2013-08-27 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2/CCR9
|
|
US7671062B2
(en)
|
2006-07-28 |
2010-03-02 |
Bristol-Myers Squibb Company |
Modulators of chemokine receptor activity, crystalline forms and process
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
JP5306344B2
(ja)
|
2007-07-12 |
2013-10-02 |
ケモセントリックス， インコーポレイテッド |
炎症の治療のためのｃｃｒ２モジュレーターとしての縮合ヘテロアリールピリジルおよびフェニルベンゼンスルホンアミド
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
MX2011006226A
(es)
|
2008-12-10 |
2011-06-24 |
Janssen Pharmaceutica Nv |
Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol del receptor 2 de citocina quimioatrayente.
|
|
JP5844159B2
(ja)
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ |
Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
|
|
TW201105649A
(en)
|
2009-04-16 |
2011-02-16 |
Janssen Pharmaceutica Nv |
4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2
|
|
EP2419419B1
(en)
|
2009-04-17 |
2014-12-03 |
Janssen Pharmaceutica NV |
4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
|
|
ES2674275T3
(es)
|
2009-12-17 |
2018-06-28 |
Centrexion Therapeutics Corporation |
Antagonistas del receptor CCR2 y usos de los mismos
|
|
US9040526B2
(en)
|
2010-02-09 |
2015-05-26 |
Bristol-Myers Squibb Company |
Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity
|
|
WO2011141474A1
(en)
|
2010-05-12 |
2011-11-17 |
Boehringer Ingelheim International Gmbh |
Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
|
|
US8642622B2
(en)
|
2010-06-16 |
2014-02-04 |
Bristol-Myers Squibb Company |
Piperidinyl compound as a modulator of chemokine receptor activity
|
|
US8518969B2
(en)
|
2010-06-17 |
2013-08-27 |
Janssen Pharmaceutica Nv |
Cyclohexyl-azetidinyl antagonists of CCR2
|
|
SG193002A1
(en)
|
2011-03-10 |
2013-09-30 |
Daiichi Sankyo Co Ltd |
Dispiropyrrolidine derivative
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
US8822460B2
(en)
|
2012-04-06 |
2014-09-02 |
Janssen Pharmaceutica Nv |
Fused cyclopentyl antagonists of CCR2
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
RU2689760C2
(ru)
|
2012-05-31 |
2019-05-30 |
Дженентек, Инк. |
Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
|
|
WO2013192596A2
(en)
*
|
2012-06-22 |
2013-12-27 |
Sorrento Therapeutics Inc. |
Antigen binding proteins that bind ccr2
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
SI3010503T1
(sl)
*
|
2013-06-21 |
2020-07-31 |
Zenith Epigenetics Ltd. |
Novi biciklični inhibitorji bromodomene
|
|
AU2014309199B2
(en)
|
2013-08-20 |
2018-04-19 |
Merck Sharp & Dohme Llc |
Treating cancer with a combination of a PD-1 antagonist and dinaciclib
|
|
CN105705489B
(zh)
|
2013-09-04 |
2019-04-26 |
百时美施贵宝公司 |
用作免疫调节剂的化合物
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
WO2016039749A1
(en)
|
2014-09-11 |
2016-03-17 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
DK3297438T3
(da)
|
2015-05-21 |
2022-01-17 |
Chemocentryx Inc |
Ccr2-modulatorer
|
|
WO2017165125A1
(en)
*
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
|
|
US10195188B2
(en)
|
2016-06-13 |
2019-02-05 |
Chemocentryx, Inc. |
Method of treating pancreatic cancer
|
|
US10251888B2
(en)
|
2016-06-13 |
2019-04-09 |
Chemocentryx, Inc. |
Method of treating pancreatic cancer
|
|
US10639284B2
(en)
*
|
2016-06-27 |
2020-05-05 |
Chemocentryx, Inc. |
Immunomodulator compounds
|
|
US20190275015A1
(en)
|
2017-09-25 |
2019-09-12 |
Chemocentryx, Inc. |
Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
|
|
CA3293051A1
(en)
|
2017-09-25 |
2026-03-02 |
Chemocentryx, Inc. |
Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
|
|
US20190269664A1
(en)
|
2018-01-08 |
2019-09-05 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|